A highly mutated SARS‑CoV‑2 lineage, BA.3.2, first identified in South Africa in November 2024, has now been reported in at least 23 countries worldwide, underscoring persistent uncertainty in the global Covid‑19 landscape.

According to a recent US Centers for Disease Control and Prevention (CDC) genomic surveillance report, BA.3.2 detections began rising in September 2025 and have since been found in traveller nasal swabs, clinical samples, and airplane wastewater across 25 US states – a key early‑warning signal for public health authorities.

This variant carries roughly 70–75 mutations in the spike protein, the part of the virus that vaccines target, raising concern about reduced neutralisation by antibodies from prior infection or vaccination. The World Health Organization (WHO) designates BA.3.2 as a Variant Under Monitoring (VUM) due to its genetic differences and potential immune escape characteristics, even though it has not yet been linked to increased hospitalisations or deaths.

The spread of the new variant reinforces the importance of up‑to‑date vaccination, vigilant surveillance of local Covid-19 activity, and early detection tools such as wastewater and traveller screening. While BA.3.2’s prevalence remains low in some regions, continued global sequencing and monitoring are critical to understanding its transmissibility and impact on vaccine effectiveness.

Airport revenue has continued to lag behind pre-Covid-19 pandemic benchmarks, according to a report by Airports Council International (ACI) World.